Correlation Between Agios Pharm and Entera Bio

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Agios Pharm and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Agios Pharm and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Agios Pharm and Entera Bio, you can compare the effects of market volatilities on Agios Pharm and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Agios Pharm with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Agios Pharm and Entera Bio.

Diversification Opportunities for Agios Pharm and Entera Bio

0.5
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Agios and Entera is 0.5. Overlapping area represents the amount of risk that can be diversified away by holding Agios Pharm and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and Agios Pharm is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Agios Pharm are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of Agios Pharm i.e., Agios Pharm and Entera Bio go up and down completely randomly.

Pair Corralation between Agios Pharm and Entera Bio

Given the investment horizon of 90 days Agios Pharm is expected to generate 0.52 times more return on investment than Entera Bio. However, Agios Pharm is 1.91 times less risky than Entera Bio. It trades about -0.04 of its potential returns per unit of risk. Entera Bio is currently generating about -0.05 per unit of risk. If you would invest  3,303  in Agios Pharm on December 28, 2024 and sell it today you would lose (275.00) from holding Agios Pharm or give up 8.33% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Agios Pharm  vs.  Entera Bio

 Performance 
       Timeline  
Agios Pharm 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Agios Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's forward indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.
Entera Bio 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Agios Pharm and Entera Bio Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Agios Pharm and Entera Bio

The main advantage of trading using opposite Agios Pharm and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Agios Pharm position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.
The idea behind Agios Pharm and Entera Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio